Antileukaemic

Toddaculine
Catalog No: CFN92733

Toddaculine may be beneficial for the prevention and treatment of osteoporosis, it can not only inhibit the differentiation of osteoclasts via activation of the NF-κB, ERK 1/2, and p38 MAPK signaling pathways, but can induce differentiation and mineralization of osteoblasts by regulating differentiation factors. Toddaculine also may serve as a pharmacological prototype for the development of novel anti-leukemic agents, it displays a dual effect as a cell differentiating agent and apoptosis inducer in U-937 cells.
Dehydroeburicoic acid
Catalog No: CFN92740

Dehydroeburicoic acid induces necrotic cell death that involves Ca(2+) overload, mitochondrial dysfunction, and calpain activation in human glioblastomas. Dehydroeburicoic acid and Eburicoic acid have antioxidant and anti-inflammatory activities by the decrease of inflammatory cytokines and an increase of antioxidant enzyme activity, can protect the liver from CCl4-induced hepatic damage.
14-Deoxycoleon U
Catalog No: CFN97924

14-Deoxycoleon U has anti-termitic activity, it is highly active against both wood-decay fungi. 14-Deoxycoleon U shows antibacterial activity against the Gram-positive bacteria Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, and Micrococcus luteus.
Deguelin
Catalog No: CFN97934

Deguelin, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.
Deguelin is a potent in vitro inhibitor of the mutant form of NPM1, which provides the molecular basis for its anti-leukemia activities in NPM1 mutant acute myeloid leukemia cells.Deguelin has anti-cancer activity, such as anti osteosarcoma, lung cancer; via inducing the apoptosis of cancer cells through a ROS driven Akt pathway, EPC suppression by FAK-integrin-ILK-dependent actin remodeling .Deguelin possesses antitumor effect by targeting Akt in dual axis such as EGFR and IGF1R signaling pathways and suggests that it provides an applicable therapeutic strategy for HNSCC patients.
Bruceine D
Catalog No: CFN90771

Bruceine D has anti-cancer activity, it inhibits the growth of three pancreatic cancer cell lines, i.e., PANC-1, SW1990 and CAPAN-1; induces cytotoxicity in Capan-2 cells via the induction of cellular apoptosis involving the mitochondrial pathway.Bruceine D may have the potential to be used as a natural viricide, or a lead compound for new viricides.